Celyad Oncology SA
Celyad Oncology SA is a biotechnology company focused on the development of cell therapy products for the treatment of cancer, primarily through its lead candidate, Tecartus (brexucabtagene autoleucel), which is approved for the treatment of adult patients with B-cell precursor acute lymphoblastic leukemia.
Business. Celyad Oncology SA (CYAD.BR) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in Belgium and is primarily listed on the Euronext Brussels exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Celyad Oncology SA (CYAD.BR) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in Belgium and is primarily listed on the Euronext Brussels exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Celyad's capital structure is characterized by a lack of dilution risk, as the number of basic and diluted shares outstanding is identical at 44,761,905, indicating no dilutive impact from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability and returns are not currently available for Celyad, as the valuation snapshot does not provide metrics such as ROIC or EBITDA margins. This lack of data makes it difficult to compare the company's performance against industry_config preferred metrics or cohort medians.
Celyad's revenue concentration is not disclosed in the available data, but as a biotechnology company, it is likely to be heavily dependent on a small number of products or partnerships. The company's lead product, Tecartus, is a key revenue driver, and its performance is critical to the company's financial health.
Growth trajectory is not quantified in the available data, but the company's focus on cell therapy and its approval of Tecartus suggest potential for expansion in the oncology market. However, without specific revenue history or outlook figures, it is difficult to assess the company's growth prospects.
Risk factors include the inability to assess liquidity risk and the potential for regulatory or market risks associated with its biotechnology operations. The company's reliance on a single product and the competitive nature of the biotechnology industry also pose significant risks.
Recent events include the continued development and commercialization of Tecartus, but no specific filings or transcripts are cited in the available data to provide further insight into the company's recent activities.
- Celyad's capital structure shows no dilution risk, with basic and diluted shares outstanding being equal.
- Profitability and returns data are not available, making it difficult to assess the company's performance against industry benchmarks.
- The company's revenue is likely concentrated on its lead product, Tecartus, which is critical to its financial health.
- Growth trajectory is not quantified, but the company's focus on cell therapy suggests potential for expansion.
- Liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
- The company faces regulatory and market risks typical of the biotechnology industry.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue €0.00; Operating income −54,8% YoY.
- ▍Revenue €0.00
- ▍Operating income −54,8% YoY
- ▍Net income −54,4% YoY
- ▍Free cash flow −56,1% YoY
Revenue €0.00; Operating income -€26.4M.
- ▍Revenue €0.00
- ▍Operating income -€26.4M
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Celyad Oncology SA Market data — financials · 2026-05-27
- Celyad Oncology SA Market data — analyst estimates · 2026-05-27